Where It’s Really At : Telaria, Inc. (TLRA), Protalix BioTherapeutics, Inc. (PLX)
The stocks of Telaria, Inc. (NYSE:TLRA) has been Initiated to Overweight by Stephens in its latest research note that was published on November 05. The stock also received a Buy rating from Lake Street with the price target of $6 to $7. This was contained in a research note published by the firm on February 27. The stock received a Buy rating and a price target of $4 to $6.25 in B. Riley FBR’s research note that was published on February 27.
Telaria,’s stock is covered by 5 analysts, with 5 of them rating the stock as Buy. It has been deemed to have strong buy by none of the analysts, none of them have rated it as a Hold while none of them rated it as sell. Meanwhile, none analyst(s) rated it as a sell. The above data shows that TLRA has an average analyst rating of Buy.
Telaria, Inc., ...